Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of 3-Hydroxycoumarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 4/20 | 0.53 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.86 |
| ▸ | TYR | P14679 | 1/20 | 0.86 |
| ▸ | DAO | P14920 | 1/20 | 0.86 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.86 |
| ▸ | CA12 | O43570 | 4/20 | 0.60 |
| ▸ | CA9 | Q16790 | 4/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Hydroxycoumarin SCHEMBL76090 | 0.93 | HPGD (1.00) | HPGDTYRDAOAKR1B1CA12 | |
| 3-Hydroxycoumarin SCHEMBL29397603 | 0.93 | HPGD (1.00) | HPGDTYRDAOAKR1B1CA12 | |
| 3-Hydroxycoumarin SCHEMBL28258929 | 0.91 | HPGD (0.96) | HPGDTYRDAOAKR1B1CA12 | |
| 3-Hydroxycoumarin SCHEMBL31476361 | 0.87 | HPGD (0.89) | HPGDTYRDAOAKR1B1CA12 | |
| 3-Hydroxycoumarin SCHEMBL28145356 | 0.87 | HPGD (0.89) | HPGDTYRDAOAKR1B1CA12 | |
| 3-Hydroxycoumarin SCHEMBL28186257 | 0.86 | HPGD (0.86) | HPGDTYRDAOAKR1B1CA12 | |
| 3-Hydroxycoumarin SCHEMBL28805372 | 0.86 | HPGD (0.86) | HPGDTYRDAOAKR1B1CA12 | |
| 3-Hydroxycoumarin SCHEMBL27836527 | 0.86 | HPGD (0.86) | HPGDTYRDAOAKR1B1CA12 | |
| 3-Hydroxycoumarin SCHEMBL16011243 | 0.86 | HPGD (0.86) | HPGDTYRDAOAKR1B1CA12 | |
| 3-Hydroxycoumarin SCHEMBL31476360 | 0.84 | HPGD (0.83) | HPGDTYRDAOAKR1B1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069557-A1 | STABLE TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-12491170-B2 | Stable treprostinil prodrugs | UNITED THERAPEUTICS CORPORATION (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250154181-A1 | TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2025-05-15 | — | — | US | disclosed |
| US-12173021-B2 | Treprostinil prodrugs | UNITED THERAPEUTICS CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240130989-A1 | STABLE TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240051979-A1 | TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2024-02-15 | — | — | US | disclosed |
| US-11826328-B2 | Stable treprostinil prodrugs | UNITED THERAPEUTICS CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4259121-A1 | METHODS OF TREATING DISEASE WITH TREPROSTINIL PRODRUGS | United Therapeutics Corporation (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11634443-B2 | Treprostinil prodrugs | UNITED THERAPEUTICS CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220323387-A1 | STABLE TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2022-10-13 | — | — | US | disclosed |
| WO-2022132655-A1 | METHODS OF TREATING DISEASE WITH TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021041320-A1 | TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210054009-A1 | TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2021-02-25 | — | — | US | disclosed |
| EP-1815244-A4 | CELL CULTURE DEVICE | AGENCY SCIENCE TECH & RES (SG) | 2009-07-22 | — | — | EP | disclosed |
| US-20080292584-A1 | METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7378434-B2 | Metaxalone products, method of manufacture, and method of use | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1815244-A1 | CELL CULTURE DEVICE | Agency for Science, Technology and Research (SG) | 2007-08-08 | — | — | EP | disclosed |
| US-20070088066-A1 | Metaxalone products, method of manufacture, and method of use | MPC OLDCO, INC. | 2007-04-19 | — | — | US | disclosed |
| US-7122566-B1 | Metaxalone products, method of manufacture, and method of use | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2006052223-A1 | CELL CULTURE DEVICE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154181-A1 | TREPROSTINIL PRODRUGS | TYMP, TK1, DCTPP1 | MAOB 1114/4885MAOA 1353/4885HPGD 16/4885 |
| US-20210054009-A1 | TREPROSTINIL PRODRUGS | TYMP, TK1, DCTPP1 | MAOB 1114/4885MAOA 1353/4885HPGD 16/4885 |
| US-11826328-B2 | Stable treprostinil prodrugs | TYMP, TK1, TREH | MAOB 1473/4885MAOA 1770/4885HPGD 35/4885 |
| US-20220323387-A1 | STABLE TREPROSTINIL PRODRUGS | TYMP, TK1, TREH | MAOB 1473/4885MAOA 1770/4885HPGD 35/4885 |
| US-20240051979-A1 | TREPROSTINIL PRODRUGS | TYMP, TK1, DCTPP1 | MAOB 1114/4885MAOA 1353/4885HPGD 16/4885 |
| US-20260069557-A1 | STABLE TREPROSTINIL PRODRUGS | NUDT1, TNNC1, PNP | MAOB 1951/4885MAOA 2960/4885HPGD 572/4885 |
| US-20240130989-A1 | STABLE TREPROSTINIL PRODRUGS | TYMP, TK1, TREH | MAOB 1473/4885MAOA 1770/4885HPGD 35/4885 |
| US-12173021-B2 | Treprostinil prodrugs | TYMP, TK1, DCTPP1 | MAOB 1114/4885MAOA 1353/4885HPGD 16/4885 |
| US-11634443-B2 | Treprostinil prodrugs | TYMP, TK1, DCTPP1 | MAOB 1114/4885MAOA 1353/4885HPGD 16/4885 |
| US-12491170-B2 | Stable treprostinil prodrugs | TYMP, TK1, TREH | MAOB 1473/4885MAOA 1770/4885HPGD 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.